Citations

Clear

91 citation(s) found for "Steffen, F".

Prognostic Impact of SCAI Shock Severity Classes in AMI-Related Cardiogenic Shock: A Sub-Study of the ECLS-SHOCK Trial
Pöss, Janine, Desch, Steffen , Feistritzer, Hans‐Josef , Freund, Anne, Roßberg, Michelle , Jung, Christian , Ouarrak, Taoufik , Thevathasan, Tharusan , Zeymer, Uwe , Thiele, Holger , Jentzer, Jacob, Jung, Christian , Jentzer, Jacob C. , Freund, Anne , Schneider, Steffen, Akin, Ibrahim , Rassaf, Tienush

Mayo Clinic

ESC Heart Failure | October 14, 2025 | Volume: 12 | Issue: 6 | Pages: 4359-4368

10.1002/ehf2.15446 | PMID 41083288 Get It

Abstract Aims The Society for Cardiovascular Angiography and Interventions (SCAI) Classification provides risk stratification of patients with acute myocardial infarction complicated by cardiogenic shock (AMI-CS). This sub-study of the ECLS-SHOCK trial investigates the prognostic impact of SCAI stages in AMI-CS and the influence of SCAI stages on the effect of extracorporeal life support (ECLS) therapy in AMI-CS patients. Methods Patients with AMI-CS enrolled in the multicentre, randomized ECLS-SHOCK trial were included. The outcomes, treatment effect and safety of ECLS were stratified according to SCAI stage at admission using a post-hoc classification. Results From a total of 417 patients enrolled in the ECLS-SHOCK trial between June 2019 and November 2022, 51.6% (n = 215), 13.4% (n = 56) and 35.0% (n = 146) presented in SCAI Stages C, D and E, respectively. SCAI stages were associated with the risk of 30 day all-cause mortality (C vs. D vs. E: 32.6% vs. 67.9% vs. 64.4%, P < 0.001), with rates of renal replacement therapy at 30 days (C vs. D vs. E: 7.0% vs. 19.6% vs. 13.7%, P = 0.03) and with poor neurological outcomes (C vs. D vs. E: 17.2% vs. 44.4% vs. 36.5%, P < 0.001). No interaction was observed between SCAI stage and the treatment effect of ELCS on 30 day all-cause mortality (ELCS vs. control SCAI C: 32.7% vs. 32.4%; SCAI D: 68.4% vs. 66.7%; SCAI E: 59.7% vs. 68.4%, P for interaction = 0.65). Conclusions In AMI-CS patients included in the ECLS-SHOCK trial, SCAI stages at admission were predictive for mortality and for the incidence of safety events. The efficacy of ECLS treatment was not affected by SCAI stage.
Investigation of DNA Damage Response Genes Validates the Role of DNA Repair in Pediatric Cancer Risk and Identifies SMARCAL1 as a Novel Osteosarcoma Predisposition Gene
Oak, Ninad , Chen, Wenan , Blake, Alise K. , Harrison, Lynn , O’Brien, Martha A., Previti, Christopher , Balasubramanian, Gnanaprakash, Hirsch, Steffen , Penkert, Judith , Jones, Barbara C. , Schramm, Kathrin , Nathrath, Michaela , Witt, Olaf , Li, Jiaming , Ness, Kirsten K. , Kratz, Christian P. , Armstrong, Greg , Autry, Robert J. , Nichols, Kim E. , Armstrong, Gregory T. , Blake, Alise , Hirsch, Steffen , Penkert, Judith , Jones, Barbara C , Nathrath, Michaela , Pajtler, Kristian W , Jones, David T W , Witt, Olaf , Dirksen, Uta , Li, Jiaming , Sapkota, Yadav , Ness, Kirsten K , Guenther, Lillian M , Kratz, Christian , Wang, Zhaoming , Hudson, Melissa M , Wu, Gang , Nichols, Kim E , Sharma, Richa , O'Brien, Martha, Maaß, Kendra K. , Pajtler, Kristian W. , Jones, David , Sapkota, Yadav , Pfister, Stefan M. , Wang, Zhaoming , Hudson, Melissa M. , Wu, Gang , Sharma, Richa

Mayo Clinic

Journal of Clinical Oncology | October 9, 2025 | Volume: 43 | Issue: 36 | Pages: 3833-3843

10.1200/jco-25-01114 | PMID 41066719 Get It

PURPOSE Recent studies reveal that 5%-18% of children with cancer harbor pathogenic variants in known cancer-predisposing genes. However, DNA damage repair (DDR) genes, which are frequently somatically altered in pediatric tumors, have not been systematically examined as a source of novel cancer-predisposing signals. METHODS To address this gap, we interrogated 189 DDR genes for presence of germline predisposing variants (PV) among 5,993 childhood cancer cases and 14,477 adult noncancer controls (discovery cohort). PV were determined using a tiered approach incorporating ClinVar annotations, InterVar classification, and in silico tools (REVEL, CADD, and MetaSVM). Using logistic and firth regression, we identified genes with PV statistically enriched in the germline of children with tumors and replicated findings among 1,497 additional childhood cancer cases across three independent cohorts. RESULTS Analysis across all cases with cancer revealed enrichment of TP53 PV. Cancer-specific analyses confirmed known associations including germline TP53 PV in adrenocortical carcinoma, high-grade glioma (HGG), and medulloblastoma (MB), PMS2 in HGG and non-Hodgkin lymphoma (NHL), MLH1 in HGG, BRCA2 in NHL, and BARD1 in neuroblastoma. In addition, four novel associations were uncovered, including BRCA1 in ependymoma, SPIDR in HGG, SMC5 in MB, and SMARCAL1 in osteosarcoma (OS). Importantly, the SMARCAL1 :OS association was significant in the discovery (6/230, 2.6%, false discovery rate [FDR] logistic = 0.0189) as well as all three replication cohorts (Childhood Cancer Survivor Study: 8/275, 2.9%; P Fisher < .0001; Cancer Predisposition Syndrome-German Childhood Cancer Registry: 4/135, 3%, P Fisher = .002; Individualized Therapy for Relapsed Malignancies in Childhood: 4/217, 1.8%, P Fisher = .012). The remaining wild-type SMARCAL1 allele was deleted in three of four OS tumors with available data. CONCLUSION Our study confirms the relevance DDR genetic variation in pediatric cancer risk and establishes SMARCAL1 as a novel OS predisposing gene, providing insights into tumor biology and creating opportunities to optimize care for patients with this challenging tumor.
Prevalence and Clinical Implications of Sleep Apnea in Hypertrophic Cardiomyopathy
Venkataraman, Shreyas , Deshmukh, Abhishek , Siontis, Konstantinos C. , Konecny, Thomas, Somers, Virend K., Karim, Shahid , Mansukhani, Meghna, Karim, Shahid, Chahal, C. Anwar A. , Mansukhani, Meghna P. , Khanji, Mohammed Y , Petersen, Steffen E. , Gersh, Bernard J. , Geske, Jeffrey B.

Mayo Clinic

JAMA Cardiology | September 3, 2025 | Volume: 10 | Issue: 10 | Pages: 1024

10.1001/jamacardio.2025.2877 | PMID 40900558 Get It

Importance Sleep disordered breathing (SDB) is a well-established contributor to cardiovascular morbidity, mediated by intermittent hypoxemia, autonomic dysregulation, and endothelial dysfunction. Patients with hypertrophic cardiomyopathy (HCM) may be especially at risk for SDB, but the clinical impact of SDB in this population remains unclear. Objective To define the prevalence and subtypes of SDB in HCM and examine their association with echocardiographic parameters and cardiac biomarker expression. Design, Setting, and Participants A prospective cohort study was conducted between April 18, 2018, and January 15, 2024, at a single tertiary referral center specializing in HCM care. Adults with HCM (left ventricular wall thickness ≥15 mm or pathogenic variants) were recruited from an institutional registry. Patients diagnosed with SDB or current pregnancy were excluded. Patients underwent polysomnography, with comparative assessment of echocardiographic, electrocardiographic, and biomarker indices. Observers were blinded to polysomnographic results. Data analysis was performed from April 11, 2024, to July 25, 2024. Exposures SDB classified via polysomnography using apnea-hypopnea index thresholds, with subtypes including obstructive sleep apnea and central sleep apnea and with event severity, hypoxemia, and sleep architecture disruption quantified. Main Outcomes and Measures Echocardiographic indices, cardiac biomarker expression, functional status, apnea-hypopnea index, and overnight hypoxemia. Results Among 154 patients (median [IQR] age, 60 [48-68] years; 102 [66.2%] male), 91 (59.1%) were diagnosed with SDB. Those with SDB, compared with those without SDB, had higher left ventricular mass index (median [IQR], 128 [107-161] vs 109 [96-134] g/m 2 ; P = .03), E/e′ ratio (median [IQR], 12.5 [10.0-15.0] vs 10.0 [8.3-14.5]; P = .04), and baseline troponin-T level (median [IQR], 0.013 [0.009-0.022] vs 0.011 [0.007-0.015] ng/mL [to convert to micrograms per liter, multiply by 1]; P = .04) and greater overnight troponin-T level increases (change in median [IQR], 0.0021 [−0.0029 to 0.0062] vs 0.0002 [−0.0022 to 0.0026] ng/mL; P = .02). New York Heart Association class II or III symptoms were more common in those with SDB (48 [52.7%] vs 17 [27.0%]; P = .005). Hypertension and diabetes were more prevalent among patients with SDB than without SDB (hypertension: 67 [73.6%] vs 36 [57.1%]; P = .03; diabetes: 14 [15.4%] vs 3 [4.8%]; P = .04), whereas rates of atrial fibrillation and prior myectomy did not differ significantly between groups. Conclusions and Relevance This study suggests that undiagnosed SDB is highly prevalent in patients with HCM and that SDB is associated with adverse myocardial remodeling, greater diastolic dysfunction, and elevated troponin-T levels, indicating subclinical myocardial injury. SDB may contribute to HCM pathophysiology and symptom burden, supporting the rationale for randomized clinical trials to determine the impact of treating SDB on symptoms and clinical outcomes in patients with HCM.
Left ventricular wall thickness heterogeneity improves cardiovascular disease diagnosis and prognosis: a UK Biobank cardiovascular magnetic resonance cohort study
Hesse, Kerrick , Khanji, Mohammed Y , Chahal, C. Anwar A. , Petersen, Steffen E. , Aung, Nay , Chahal, Choudhary Anwar A , Khanji, Mohammed Yunus , Petersen, Steffen E , Aung, Nay

Mayo Clinic

European Heart Journal - Imaging Methods and Practice | July 18, 2025 | Volume: 3 | Issue: 2 | Pages: No page available

10.1093/ehjimp/qyaf092 | PMID 40740418 Get It

Abstract Aims Left ventricular hypertrophy (LVH) regionality carries diagnostic and prognostic importance. Mean absolute deviation of maximum segmental wall thickness (MadWT) is a novel left ventricular wall thickness (LVWT) heterogeneity biomarker from cardiovascular magnetic resonance imaging (CMR). Objectives To compare MadWT to indexed LV mass (LVMi), maximum (MaxWT) and mean (MeanWT) wall thickness to predict incident cardiovascular disease (CVD) and differentiate physiological from pathological LVH in highly physically active individuals. Methods and results Deep learning-assisted analysis of 44 930 UK Biobank CMR scans produced WT indices. Cox regression modelled major adverse cardiovascular events (MACE), heart failure (HF), arrhythmia, and all-cause death against LVWT indices. In the top 1% most physically active biomarker differences between propensity score matched hypertensive and non-hypertensive groups were compared. Over median (Q1, Q3) follow-up of 5.7 (4.9, 7.1) years, MadWT, MaxWT, MeanWT, and LVMi were associated with greater risk of MACE, HF, arrhythmia (P &lt; 0.05), but not all-cause death (P &gt; 0.05). After adjusting for CMR biomarkers, including LVMi, MadWT remained independently prognostic of the greatest number of endpoints, including MACE, HF, and arrhythmia [HR 1.13 (1.04–1.23); HR 1.15 (1.01–1.32); and HR 1.26 (1.18–1.35) respectively]. In the top 1% most physically active by three metrics, MadWT was the only significantly different biomarker between hypertensive and non-hypertensive participants (P &lt; 0.05). Conclusion MadWT is important prognostically beyond LV mass and may be useful when differentiating physiological from hypertensive LVH. Although findings require confirmation in athletic and diseased cohorts, MadWT is readily translatable to deep learning-assisted clinical CMR reporting, especially in early unexplained LVH.
Artificial Intelligence‐Based Detection of Central Retinal Artery Occlusion Within 4.5 Hours on Standard Fundus Photographs
Gungor, Ayse , Sarbout, Ilias , Gilbert, Aubrey L. , Hamann, Steffen, Lebranchu, Pierre , Gohier, Philippe , Vignal‐Clermont, Catherine, Dumitrascu, Oana M. , Cohen, Salomon Y. , Lagrèze, Wolf A. , Heide, Frank van der, Lamirel, C. , Obadia, Michaël , Miléa, Dan , Gohier, Philippe , Dumitrascu, Oana M , Cohen, Salomon-Yves , Lagrèze, Wolf A , Feltgen, Nicolas , Lamirel, Cédric , Jonas, Jost B , Obadia, Michael , Racoceanu, Daniel , Milea, Dan , Hamann, Steffen , Hobeanu, Cristina , Heide, Frank C. T. van der

Mayo Clinic

Journal of the American Heart Association | June 27, 2025 | Volume: 14 | Issue: 13 | Pages: No page available

10.1161/jaha.124.041441 | PMID 40576025 Get It

Background Prompt diagnosis of acute central retinal artery occlusion (CRAO) is crucial for therapeutic management and stroke prevention. However, most stroke centers lack onsite ophthalmic expertise before considering fibrinolytic treatment. This study aimed to develop, train, and test a deep learning system to detect hyperacute CRAO on retinal fundus photographs within the critical 4.5‐hour treatment window and up to 24 hours after visual loss to aid in secondary stroke prevention. Methods Our retrospective, cross‐sectional study included 1322 color fundus photographs from 771 patients with acute visual loss due to CRAO, central retinal vein occlusion, nonarteritic anterior ischemic optic neuropathy, and healthy controls. Photographs were collected from 9 expert neuro‐ophthalmology centers in 6 countries, including 3 randomized clinical trials. Training included 1039 photographs (517 patients), followed by testing on 2 data sets: (1) hyperacute CRAO (54 photographs, 54 patients) and (2) CRAO within 24 hours after visual loss (110 photographs, 109 patients). Results The deep learning system achieved an area under the receiver operating characteristic curve of 0.96 (95% confidence interval (CI), 0.95–0.98), a sensitivity of 92.6% (95% CI, 87.0–98.0), and a specificity of 85.0% (95% CI, 81.8–92.8) for detecting CRAO at hyperacute stage, with similar results within 24 hours. The deep learning system outperformed stroke neurologists on a subset of hyperacute testing data set (120 photographs, 120 patients). Conclusions A deep learning system can accurately detect hyperacute CRAO on retinal photographs within a time window compatible with urgent fibrinolysis. If further validated, such systems could improve patient selection for fibrinolytic trials and optimize secondary stroke prevention. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06390579.
Clinical use and reporting of neurofilament quantification in neurological disorders: A global overview
Delaby, Constance , Martinez‐Yriarte, Jose, Zecca, Chiara , Körtvelyessy, Péter , Tumani, Hayrettin , Quadrio, Isabelle , Hart, Melanie , Olsen, Dorte Aalund , Alcolea, Daniel, Blennow, Kaj , Bouaziz-Amar, Élodie , Baldeiras, Inês , Bigot‐Corbel, Edith , Bjerke, Maria , Perez, Mercedes Carretero, Chabrashvili, Tinatin, Chapman, Miles, Fourier, Anthony , Galimberti, Daniela , Gezen‐Ak, Duygu , Gouju, Julien , Flórez, Silvia de las Heras , Sanchez, Juanjo Hernandez, Herwerth, Marina , Imperiale, Daniele , Kaczorowski, Flora, Keshavan, Ashvini , Leithner, Christoph , Blanc, M, Rodríguez, Jose Enrique Martínez, Musso, Giulia , Nogueira, Léonor, Garay, Raquel Perez, Quillard‐Muraine, Muriel, Borja, Enrique Rodriguez, Schraen, Susanna, Terracciano, Daniela , Bachhuber, Franziska , Tzartos, Socrates J., Tzartos, John , Unterwalder, Nadine, Lehmann, Sylvain , Keshavan, Ashvini , Galimberti, Daniela , Herwerth, Marina , Ladang, Aurélie , Logroscino, Giancarlo , Tumani, Hayrettin , Parchi, Piero , Alcolea, Daniel , Fortea, Juan , Lleó, Alberto , Algeciras‐Schimnich, Alicia , Ayrignac, Xavier , Bedel, Aurélie , Santos, Gustavo Alves Andrade dos , Borelli, Wyllians Vendramini , Perez, Mercedes Carretero, Casoli, Tiziana , Cusato, Jessica , Dursun, Erdinç , Gordon, Brian A. , Sanchez, Juanjo Hernandez, Kasuga, Kensaku , Khalil, Michael , Kühle, Jens , Lewczuk, Piotr , Letournel, Franck , Tsolaki, Magda , Giuffrè, Guido Maria , Mroczko, Barbara , Kulczyńska‐Przybik, Agnieszka , Paquet, Claire , Baiardi, Simone , Gaetani, Lorenzo , Parnetti, Lucilla , Poesen, Koen , Halbgebauer, Steffen , Vermunt, Lisa , Wellington, Cheryl L. , Zetterberg, Henrik , Teunissen, Charlotte E.

Mayo Clinic

Alzheimer's & Dementia | June 23, 2025 | Volume: 21 | Issue: 6 | Pages: No page available

10.1002/alz.70343 | PMID 40551293 Get It

Abstract INTRODUCTION Neurofilament light chain (NfL) quantification aids in diagnosing and predicting neurological disorders, but clinical and laboratory practices vary across centers. Differences in result interpretation and reporting further challenge test commutability. This study aimed to review the global analytical and post‐analytical methods used for NfL measurement in routine clinical practice across different contexts. METHODS We established an international working group (WG) and distributed a survey to its members to gather information on context of use (COU), (pre) analytical methods, cutoff usage, as well as the interpretation and reporting of NfL measurements. RESULTS Among the centers, 63% measured NfL in cerebrospinal fluid (CSF), 87% in blood, and 53% in both. COU was widespread, with 50% defining pathological cutoffs based on publications and 42% considering age. Reporting was primarily done through numeric results (95%). DISCUSSION Harmonizing cutoffs, reporting, and interpretation across various clinical contexts will facilitate the incorporation of this biomarker into routine clinical practice. Highlights Unique international overview of current analytical and post‐analytical methods for neurofilament light chain (NfL) measurement in routine clinical practice. Tailored sheets for each neurological application. Strategies to harmonize cutoffs, reporting, and interpretation of NfL's measurement.
European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis.
Vannucchi, Alessandro M. , Mascarenhas, John , Bose, Prithviraj , Gale, Robert Peter , Harrison, Claire , Hehlmann, Rüdiger , Koschmieder, Steffen , Tefferi, Ayalew , Barbui, Tiziano , Vannucchi, Alessandro M , Mascarenhas, John , Gale, Robert P , Bose, Prithviraj , Koschmieder, Steffen , Marchetti, Monia , Álvarez‐Larrán, Alberto , Hehlmann, Rűdiger, Kiladjian, Jean‐Jacques , Mesa, Ruben A. , Passamonti, Francesco , Rambaldi, Alessandro

Mayo Clinic

No container title available | June 6, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6785954/v1 Get It

Abstract Most myelofibrosis (MF) drug approvals by Health Authorities are based on 1 or 2 outcome measures such as spleen volume reduction and/or improved quality-of-life. This 1–2 dimensional approach fails to capture the clinical complexity of MF. A European LeukemiaNet (ELN) taskforce developed a composite endpoint which allows multiple outcomes to be simultaneously measured. The panel used the Desirability-Of-Outcome-Ranking (DOOR) method to assign 25 outcomes into 4 quartiles based on a multi-dimensional desirability score and build a 5-layer composite outcome named Desirability-of-Myelofibrosis-Outcomes (DEMYO). Outcome operational definitions were tested by Delphi consensus and correlations with survival validated by a literature review. The outcomes assigned to the first two quartiles were negatively correlated with leukemia-free survival and survival. DEMYO comprehensively captures relevant MF clinical features and meaningful endpoints. Despite DEMYO requires validation based on available trial data, it is expected to improve the quality of Health Authority approvals for new drugs for MF.
Diagnostic and prognostic value of ECG-predicted hypertension-mediated left ventricular hypertrophy using machine learning
Pujadas, Esmeralda Ruiz , Aung, Nay , Chamling, Bishwas , Markus, Marcello Ricardo Paulista , Chahal, Choudhary Anwar A., Aung, Nay , Markus, Marcello R P , Aung, Nay , Naderi, Hafiz , Ramírez, Julia , Duijvenboden, Stefan van , Wang, Lin , Dörr, Marcus , Chahal, Choudhary Anwar A., Lekadir, Karim , Petersen, Steffen E. , Munroe, Patricia B.

Mayo Clinic

Journal of Hypertension | May 23, 2025 | Volume: 43 | Issue: 8 | Pages: 1327-1338

10.1097/hjh.0000000000004034 | PMID 40407114 Get It

Objective: Four hypertension-mediated left ventricular hypertrophy (LVH) phenotypes have been reported using cardiac magnetic resonance (CMR): normal LV, LV remodelling, eccentric and concentric LVH, with varying prognostic implications. The electrocardiogram (ECG) is routinely used to detect LVH; however, its capacity to differentiate between LVH phenotypes is unknown. This study aimed to classify hypertension-mediated LVH from the ECG using machine learning and test for associations of ECG-predicted phenotypes with incident cardiovascular outcomes. Methods: ECG biomarkers were extracted from the 12-lead ECG of 20 439 hypertensive patients in UK Biobank (UKB). Classification models integrating ECG and clinical variables were built using logistic regression, support vector machine (SVM), and random forest. The models were trained in 80% of the participants, and the remaining 20% formed the test set. External validation was sought in 877 hypertensive participants from the Study of Health in Pomerania (SHIP). In the UKB test set, we tested for associations between ECG-predicted LVH phenotypes and incident major adverse cardiovascular events (MACE) and heart failure. Results: Among UKB participants 19 408 had normal LV, 758 LV remodelling, 181 eccentric and 92 concentric LVH. Classification performance of the three models was comparable in UKB. SVM (accuracy 0.79, sensitivity 0.59, specificity 0.87, AUC 0.69) was taken forward for external validation with similar results in SHIP. There was superior prediction of eccentric LVH in both cohorts. In the UKB test set, ECG-predicted eccentric LVH was associated with heart failure (hazard ratio 3.42, 95% CI 1.06–9.86). Conclusion: ECG-based ML classifiers represent a potentially accessible screening strategy for the early detection of hypertension-mediated LVH phenotypes.
Autonomic Cardiovascular Control in Health and Disease
Somers, Virend K., Karim, Shahid, Chahal, C. Anwar A. , Khanji, Mohammed Y , Petersen, Steffen E.

Mayo Clinic

Comprehensive Physiology | April 3, 2025 | Volume: 13 | Issue: 2 | Pages: 4493-4511

10.1002/j.2040-4603.2023.tb00257.x Get It

Abstract Autonomic neural control of the cardiovascular system is formed of complex and dynamic processes able to adjust rapidly to mitigate perturbations in hemodynamics and maintain homeostasis. Alterations in autonomic control feature in the development or progression of a multitude of diseases with wide‐ranging physiological implications given the neural system's responsibility for controlling inotropy, chronotropy, lusitropy, and dromotropy. Imbalances in sympathetic and parasympathetic neural control are also implicated in the development of arrhythmia in several cardiovascular conditions sparking interest in autonomic modulation as a form of treatment. A number of measures of autonomic function have shown prognostic significance in health and in pathological states and have undergone varying degrees of refinement, yet adoption into clinical practice remains extremely limited. The focus of this contemporary narrative review is to summarize the anatomy, physiology, and pathophysiology of the cardiovascular autonomic nervous system and describe the merits and shortfalls of testing modalities available. © 2023 American Physiological Society. Compr Physiol 13:4493‐4511, 2023.